Therapeutic Effects of Fibroblast Growth Factor-21 on Diabetic Nephropathy and the Possible Mechanism in Type 1 Diabetes Mellitus Mice
Wenya Weng (Weng W), Tingwen Ge (Ge T), Yi Wang (Wang Y), Lulu He (He L), Tinghao Liu (Liu T), Wanning Wang (Wang W), Zongyu Zheng (Zheng Z), Lechu Yu (Yu L), Chi Zhang (Zhang C), Xuemian Lu (Lu X)
Diabetes Metab J. 2020;44(4):566-580.   Published online 2020 May 15     DOI: https://doi.org/10.4093/dmj.2019.0089
Citations to this article as recorded by Crossref logo
New developments in the biology of fibroblast growth factors
David M. Ornitz, Nobuyuki Itoh
WIREs Mechanisms of Disease.2022;[Epub]     CrossRef
SIRT1–SIRT7 in Diabetic Kidney Disease: Biological Functions and Molecular Mechanisms
Wenxiu Qi, Cheng Hu, Daqing Zhao, Xiangyan Li
Frontiers in Endocrinology.2022;[Epub]     CrossRef
Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases
Min-Qi Jia, Cha-Xiang Guan, Jia-Hao Tao, Yong Zhou, Liang-Jun Yan
Oxidative Medicine and Cellular Longevity.2022; 2022: 1.     CrossRef
FGF21 and Chronic Kidney Disease
João Victor Salgado, Miguel Angelo Goes, Natalino Salgado Filho
Metabolism.2021; 118: 154738.     CrossRef
The Multiple Roles of Fibroblast Growth Factor in Diabetic Nephropathy
Junyu Deng, Ye Liu, Yiqiu Liu, Wei Li, Xuqiang Nie
Journal of Inflammation Research.2021; Volume 14: 5273.     CrossRef
Therapeutic effect and mechanism of combined use of FGF21 and insulin on diabetic nephropathy
Fanrui Meng, Yukai Cao, Mir Hassan Khoso, Kai Kang, Guiping Ren, Wei Xiao, Deshan Li
Archives of Biochemistry and Biophysics.2021; 713: 109063.     CrossRef
FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
Emma Henriksson, Birgitte Andersen
Frontiers in Endocrinology.2020;[Epub]     CrossRef
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman, Tim Rolph
Frontiers in Endocrinology.2020;[Epub]     CrossRef